| Subject |
Date
(D/M/Y) |
|
This link will open in a new windowWarfarin: be alert to the risk of drug interactions with tramadol (Letter to Healthcare Professionals)
|
21-6-2024 |
|
This link will open in a new windowA probably locally acquired case of dengue fever in 2024
|
19-6-2024 |
|
This link will open in a new windowCAR T-cell medicines: PRAC identifies risk of secondary malignancies of T-cell origin (Letter to Healthcare Professionals)
|
17-6-2024 |
|
This link will open in a new windowVigilance against upsurge of pertussis
|
24-5-2024 |
|
This link will open in a new windowUpdate on increased Seasonal Influenza Activity in Hong Kong
|
2-5-2024 |
|
This link will open in a new windowCHMP recommended new contraindications on the co-administration of Reyataz (Atazanavir) with encorafenib and ivosidenib, and with carbamazepine, phenobarbital, and phenytoin (Letter to Healthcare Professionals)
|
29-4-2024 |
|
This link will open in a new windowThe first local case of dengue fever in 2024
|
26-4-2024 |
|
This link will open in a new windowVigilance against B virus infection and addition of the infection to the list of “Other communicable diseases of topical public health concern”
|
5-4-2024 |
|
This link will open in a new windowEzetrol (ezetimibe) and the risks of drug-induced liver injury and severe cutaneous adverse reactions (Letter to Healthcare Professionals)
|
28-3-2024 |
|
This link will open in a new windowAmiodarone: Assessing the potential risk of primary graft dysfunction following heart transplantation (Letter to Healthcare Professionals)
|
28-3-2024 |
|
This link will open in a new windowIbrance (palbociclib): Assessing the potential risk of venous thromboembolism (Letter to Healthcare Professionals)
|
28-3-2024 |
|
This link will open in a new windowUpdated warnings of faricimab (Vabysmo): retinal vasculitis risk (Letter to Healthcare Professionals)
|
21-3-2024 |
|
This link will open in a new windowColistin (colistimethate sodium): Assessing the potential risk of pseudo-Bartter syndrome (Letter to Healthcare Professionals)
|
1-3-2024 |
|
This link will open in a new windowVigilance against upsurge of measles
|
29-2-2024 |
|
This link will open in a new windowVigilance against ceftriaxone reduced susceptible Neisseria gonorrhoeae infection
|
30-1-2024 |
|
This link will open in a new windowSafety-related information for the product Mifegyne (Letter to Healthcare Professionals)
|
25-1-2024 |
|
This link will open in a new window含mifepristone成分藥品安全資訊 (Letter to Healthcare Professionals) (Chinese only)
|
24-1-2024 |
|
This link will open in a new windowBCMA- and CD19-directed genetically modified autologous chimeric antigen receptor (CAR) T cell immunotherapies: risk of T cell malignancies (Letter to Healthcare Professionals)
|
24-1-2024 |
|
This link will open in a new windowFluoroquinolone antibiotics: must now only be prescribed when other commonly recommended antibiotics are inappropriate in the United Kingdom (Letter to Healthcare Professionals)
|
23-1-2024 |
|
This link will open in a new windowArrival of the 2023/24 Winter Influenza Season in Hong Kong
|
11-1-2024 |